SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $5 million production order and a $150 million registered direct offering, signaling strong institutional investor confidence. The community is actively discussing the implications of these developments for POET's growth in the AI infrastructure market and its potential to scale production. Discussions include comparing POET to other companies and analyzing the significance of partnerships with major industry players in photonics.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to a combination of factors, including recent earnings and a low float, leading to speculation about a potential short squeeze. The community is actively discussing price levels, profit-taking strategies, and the stock's potential for significant upward movement. Some traders are wary of the stock's history and caution against chasing gains.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors discuss the potential acquisition of Larvotto Resources and the implications of a rejected initial offer, alongside the company's existing DLA contract. Community members are debating the deal's valuation and potential government involvement, while emphasizing UAMY's position as a key domestic antimony producer amid global supply chain concerns and China's export policies. There is also growing anticipation for upcoming earnings announcements and speculation about new deals with Australia and NATO.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, potential rate cuts, and possible S&P 500 inclusion. The community is bullish, fueled by optimism around growth prospects, crypto offerings, and increasing membership. Many see a breakout above the $30 resistance level and are discussing potential price movements post-earnings.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community reminisces about the stock's past volatility and discusses potential short squeezes, drawing comparisons to other meme stocks like $BYND. A recent White House post using GameStop's slogan has further fueled the conversation and speculative interest. Traders are actively debating potential price movements and the influence of market makers.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following news of a potential acquisition by Novartis, with the deal speculated to strengthen Novartis's neuroscience pipeline. The community is buzzing about the potential buyout price, the value of the spin-off company, and the implications for the broader RNA therapeutics sector. Some traders point to options activity as a signal and congratulate long-term holders.

YPF SA engages in the exploration, production, and distribution of oil and gas. It operates through the following segments: Upstream, Gas and Power, Downstream, Central Administration and Other. The Upstream segment sells petroleum and natural gas. The Gas and Power segment markets natural gas to third parties and downstream segment; and manages commercial and technical LNG Regasification Terminals in Bahia Blanca and Escobar. The Downstream segment produces petroleum refining and petrochemicals. The Central Administration and Other segment covers corporate administrative expenses and assets, construction activities, and the environmental remediation. The company was founded on June 2, 1977 and is headquartered in Buenos Aires, Argentina.

YPF - ADR

YPF S.A.

YPF is trending due to a rally in Argentina-focused equities, sparked by Javier Milei's election victory; the community is discussing the potential impacts of his policies, including privatization and dollarization, on YPF and the broader Argentine market, while also considering technical factors and unusual options activity.

Banco BBVA Argentina SA engages in the provision of banking and financial services. It operates through the following business lines: retail banking; small and medium-sized companies; and corporate and investment banking (CIB). The retail banking business includes checking and savings accounts, time deposits, credit cards, personal and auto loans, mortgages, insurance, and investment products. The small and medium-sized companies business focuses on local private-sector companies. The CIB business covers global transaction services and global markets solutions such as risk management and securities brokerage, long term financing products as well as project finance and syndicated loans, and corporate finance services. The company was founded on October 14, 1886 and is headquartered in Buenos Aires, Argentina.

BBVA Argentina - ADR

Banco Bbva Argentina SA

BBAR is trending as investors monitor Argentinian equities following recent political developments, with some anticipating a potential rally due to a shift in leadership. Community members are actively discussing the stock's potential for significant gains, while acknowledging the inherent volatility and risks associated with the Argentinian market. The stock's low P/E ratio and the potential for increased foreign investment are also key discussion points.

Global X Funds - Global X MSCI Argentina ETF

The Argentina ETF, ARGT, is trending due to optimism surrounding Argentina's economic direction, particularly following recent political developments and government actions. Community discussions revolve around the potential impact of these changes and the fund's future performance, with some noting the country's ongoing economic challenges. Investors are closely watching how new policies will affect the fund's holdings and the broader Argentinian market.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending after successful flight testing of its Black Widow drone using Palantir's visual navigation software in GPS-denied conditions, marking a potential breakthrough for military applications. The community is actively discussing the implications of this advancement and possible contract opportunities. Some investors express excitement and long-term bullish sentiment, while others are wary of short-term volatility and are actively trading the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?

Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Praxis Precision Medicines rose 5% in premarket trading on Friday&nbsp;as bullish calls from Wall Street that were based on strong late-stage trial results for its experimental essential tremor therapy outweighed pressure from a share offering.&nbsp;&nbsp;The stock surged 184% to $162.71 on Thursday and gained another 5.3% in after-hours trading.Analysts Boost Targets Following Essential Tremor DataJefferies raised its price target on Praxis to $300 from $65, saying the firm expects “significant stock upside” following the Phase 3 ESSENTIAL3 program success in essential tremor, an indication it values as a $2.5 billion-plus opportunity. The brokerage estimated 70% odds of approval and expects Praxis to file for U.S. regulatory clearance in early 2026.Guggenheim raised its target to $350 from $155, citing the “robustness” of the data and the significant unmet need in the disorder, estimating the opportunity at over $2 billion in the U.S. and assuming an 80% probability of approval.JonesResearch made the most bullish call, hiking its price target to $441 from $83, projecting ulixacaltamide could reach blockbuster status by 2028 with potential 2032 sales of $12.2 billion, assuming U.S. approval in the first quarter of 2027.H.C. Wainwright more than doubled its target to $232 from $115, saying the trial’s positive topline data was “a big surprise” given earlier futility concerns. The firm now sees 85% odds of approval and peak sales of $3.3 billion by 2035.Oppenheimer raised its target to $250 from $115, calling the results a “double-win” and highlighting ulixacaltamide’s clean safety profile and clear regulatory path. TD Cowen followed suit, increasing its target to $251 from $61, while Truist and Baird raised theirs to $360 and $275, respectively.Ulixacaltamide’s Phase 3 Success&nbsp;Praxis said patients who received ulixacaltamide in its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-praxis-precision-medicines-stock-surge-pre-market-today/ch6pbpbR3nE">late-stage study</a> experienced a 4.3-point mean increase in Modified Activities of Daily Living 11 (mADL11) score, which is a measure of functional independence. The benefit was sustained across the entire 12-week treatment period, suggesting that patients derive a consistent benefit throughout the trial.&nbsp;Praxis said it expects to file for U.S. regulatory approval by early 2026. The drug was generally well-tolerated with no deaths or serious side effects reported in the study, though more patients in the ulixacaltamide arm discontinued the study drug due to mild or moderate reactions.Essential tremor is a neurological condition that affects about seven million people in the U.S. and has limited treatment options today. Analysts believe ulixacaltamide could become one of the first major new therapies to address this gap if approved.Capital Raise To Fund Launch PreparationsPraxis announced the pricing of a $525 million public offering late Thursday, issuing shares at $157 each and pre-funded warrants at $156.9999. The proceeds will strengthen its balance sheet ahead of regulatory filings and potential commercialization.TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering, which is expected to close on October 20, 2025.Stocktwits Traders Weigh Profit-Taking vs. Optimism After RallyOn Stocktwits, retail sentiment for Praxis was ‘extremely bullish’ amid ‘extremely high’ message volume.One retail trader said that Praxis’s $157 per-share offering looked steep, saying the company was “taking advantage of the price run” but acknowledging the move made sense given Thursday’s rally.<stembedurl>https://stocktwits.com/Ryan4vp/message/632690328</stembedurl>Another user noted that with “all the analyst upgrades,” the stock might hold up for a while despite the fundraising news.<stembedurl>https://stocktwits.com/eltrain84/message/632685557</stembedurl><a href="https://stocktwits.com/symbol/PRAX">Praxis’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Praxis’ stock (PRAX) has more than doubled so far in 2025. (Photo credit: Getty Images)

 Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win

Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data.

Equity

Futures Rise As Strong TSMC Results Reboot AI Optimism

Futures Rise As Strong TSMC Results Reboot AI Optimism Stock futures rose as an olive branch from Treasury Secretary Bessent calmed trade-war fears, while a guidance hike from chipmaker TSMC (which...

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke Therapeutics...

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction...

Praxis Precision Medicines' Promising EMBOLD Study Outcomes

The latest update is out from Praxis Precision Medicines (PRAX). Praxis Precision Medicines, Inc. has reported promising results from its EMBOLD st...

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Latest Ratings for PRAX
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021B of A SecuritiesInitiates Coverage OnBuy Apr 2021William BlairInitiates Coverage...

Analysts' Top Healthcare Picks: Immunocore Holdings (IMCR), Praxis Precision Medicines (PRAX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR Research Report) and Praxis Precision Medicines...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PRAX
Praxis Precision Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PRAX News

PRAXPraxis Precision Medicines Inc